Cidara Therapeutics Inc
NASDAQ:CDTX
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
10.17
23.2
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CDTX stock under the Base Case scenario is 19.79 USD. Compared to the current market price of 13.9 USD, Cidara Therapeutics Inc is Undervalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Cidara Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CDTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Cidara Therapeutics Inc
Balance Sheet Decomposition
Cidara Therapeutics Inc
Current Assets | 168.6m |
Cash & Short-Term Investments | 164.4m |
Receivables | 2.3m |
Other Current Assets | 1.9m |
Non-Current Assets | 4.8m |
PP&E | 4.7m |
Other Non-Current Assets | 104k |
Current Liabilities | 39.6m |
Accounts Payable | 2.3m |
Accrued Liabilities | 37.1m |
Other Current Liabilities | 265k |
Non-Current Liabilities | 2.8m |
Long-Term Debt | 445k |
Other Non-Current Liabilities | 2.3m |
Earnings Waterfall
Cidara Therapeutics Inc
Revenue
|
39.1m
USD
|
Operating Expenses
|
-75.5m
USD
|
Operating Income
|
-36.4m
USD
|
Other Expenses
|
-78.9m
USD
|
Net Income
|
-115.3m
USD
|
Free Cash Flow Analysis
Cidara Therapeutics Inc
USD | |
Free Cash Flow | USD |
CDTX Profitability Score
Profitability Due Diligence
Cidara Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Cidara Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
CDTX Solvency Score
Solvency Due Diligence
Cidara Therapeutics Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Cidara Therapeutics Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CDTX Price Targets Summary
Cidara Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for CDTX is 30.26 USD with a low forecast of 24.24 USD and a high forecast of 42 USD.
Dividends
Current shareholder yield for CDTX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. The company is headquartered in San Diego, California and currently employs 89 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The firm's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The firm's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.
Contact
IPO
Employees
Officers
The intrinsic value of one CDTX stock under the Base Case scenario is 19.79 USD.
Compared to the current market price of 13.9 USD, Cidara Therapeutics Inc is Undervalued by 30%.